TY - JOUR
T1 - Gefitinib
T2 - A new agent in palliative care
AU - Prommer, Eric
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2004
Y1 - 2004
N2 - In 2003, gefitinib (Iressa®, AstraZaneca, London, UK) in 250 mg tablet form received accelerated approval by the US Food and Drug Administration. Gefitinib targets the cancer cell at the molecular level and has the ability to palliate lung cancer symptoms. Gefitinib's ability to control symptoms with minimal toxicity provides physicians with a new option to complement current symptom control methods. It is nonmarrow suppressive and seems to have an ability to control symptoms quickly, even in the absence of obvious tumor reduction. However, further studies are needed to compare gefitinib's ability to control symptoms with intensive palliative modalities for lung cancer, such as opioids, oxygen, and radiation therapy.
AB - In 2003, gefitinib (Iressa®, AstraZaneca, London, UK) in 250 mg tablet form received accelerated approval by the US Food and Drug Administration. Gefitinib targets the cancer cell at the molecular level and has the ability to palliate lung cancer symptoms. Gefitinib's ability to control symptoms with minimal toxicity provides physicians with a new option to complement current symptom control methods. It is nonmarrow suppressive and seems to have an ability to control symptoms quickly, even in the absence of obvious tumor reduction. However, further studies are needed to compare gefitinib's ability to control symptoms with intensive palliative modalities for lung cancer, such as opioids, oxygen, and radiation therapy.
KW - Cancer pain
KW - Gefitinib
KW - Pharmacotherapy
KW - Symptom management
UR - http://www.scopus.com/inward/record.url?scp=2642551296&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2642551296&partnerID=8YFLogxK
U2 - 10.1177/104990910402100313
DO - 10.1177/104990910402100313
M3 - Review article
C2 - 15188923
AN - SCOPUS:2642551296
SN - 1049-9091
VL - 21
SP - 222
EP - 227
JO - American Journal of Hospice and Palliative Medicine
JF - American Journal of Hospice and Palliative Medicine
IS - 3
ER -